LABEST 2021 - DAY TWO

LABEST DAY 2 - Wednesday, May 26th

11:00AM - 11:30AM  KEYNOTE ADDRESS 

Martin Jarmond, The Alice Nahum Lainer Family Director of Athletics, UCLA

11:30AM - 12:15PM ADVANCING INCLUSIVE RESEARCH - AMGEN AUDITORIUM  

In order to enhance the accessibility and affordability of effective therapies, new models for the conduct of clinical trials will be discussed.

	Moderator: Jamie Freedman, Sr. Vice President of US Medical Affair, Genentech
	Dave Whelan, CEO, Bioscience LA
	Karol Watson, Director of UCLA Women's Cardiovascular Health Center
	Narimon Honarpour, Vice President & Head of Translational Medicine, AMGEN
	Melissa Archer, Director, Clinical Trials Office at the Keck School of Medicine of USC

12:00PM - 12:45PM -STARTUP ENGINES: ACADEMIC - INDUSTRY PARTNERSHIPS - KITE, A GILEAD COMPANY AUDITORIUM

Learn about new partnerships and models of collaboration between academia and industry to advance innovative research into new bioscience startups.

	Moderator: Ildiko Csiki, Chief Commercial R&D Officer, City Of Hope
	Michelle Kim-Danely, SVP Operations, Autobahn Labs
	Sunil Sharma, Physician in Chief Translational Genomics Research Institute, City of Hope
	John Delaney, Executive Director at AMGEN
	Mike Caligiuri, President of City of Hope, National Medical Center
	Mary Beth Campbell, Director of Corporate Partnerships, CalTech

12:30PM - 1:15PM MOVING MICROBES FROM BENCH TO BEDSIDE - AMGEN AUDITORIUM

An expert-led discussion of the promise of microbial-based treatments for disease while addressing the major obstacles in clinical translation and integrating microbiome-based treatments into the standard of care.

	Moderator: Elaine Hsiao, Assistant Professor, Department of Integrative Biology & Physiology, De Logi Chair in Biological Sciences, Division of Digestive Diseases, UCLA
	Sarkis Masmanian, Luis B. & Nelly Soux Professor of Microbiology, Caltech
	Denise Kelly, Investment Advisor, Seventure Partners
	Nikole Kimes - CEO, Siolta Therapeutics
	Raja Dihr, Co-Founder, Co-CEO Seed Health

1:00PM - 1:45PM IMMUNO-ONCOLOGY 2021 AND BEYOND- KITE, A GILEAD COMPANY AUDITORIUM

After three decades of research, immune-based therapies have become potent new cancer treatments. Recent advances are focused on furthering our understanding of the mechanisms of action and improving access.

	Moderator: Mike Teitell, Professor & Director UCLA Jonsson Comprehensive Cancer Center
	Robert Rickert, SVP, Chief Scientific Officer, Cancer Immunology, Pfizer
	Yvonne Chen, Co-Director, Tumor Immunology Program, Jonsson Cancer Center, UCLA
	Mohamed Abou-El-Enein, Executive Director, Joint USC/CHLA Cell Therapy Program USC
	Steven Rosen, Chief Scientific Officer, City of Hope
	Ute Dugan, Chief Medical Officer, The Parker Institute for Cancer Immunotherapy

1:30PM - 2:15PM VENTURE CAPITAL & SYNDICATION IN LOS ANGELES - AMGEN AUDITORIUM 

Learn how prominent Venture Capitalists are focusing on Los Angeles bioscience innovation and the how the increasing availability of capital is generating robust innovative startups in Los Angeles.

	Moderator: Deborah Palestrant, Head of 4:59 Ventures
	Helen S. Kim, Senior Managing Director, Vida Ventures
	Yinghong Gao, Venture Partner, Viva BioInnovator
	Sean Harper, Partner, Westlake Village BioPartners
	Kevin Barrett, Partner, Freeflow Ventures
	Nina Kjellson, General Partner, Canaan Partners